|Calculated MW||~35 kDa|
|Other Names||Advanced glycosylation end product-specific receptor, Receptor for advanced glycosylation end products, AGER|
|Sequence||Recombinant human AGER/RAGE produced by transfected human cell is a secreted protein with sequence (Ala23-Ala344) of human AGER/RAGE (Uniprot Entry: Q15109) fused with a poly-histidine tag at the C-terminus.|
|Application Notes||Dissolve in 1x PBS (It is not recommended to reconstitute to a final concentration less than 100 µg/ml.). After adding 1x PBS, let the tube stand at room temperature for 3 minutes to allow lyophilized protein to dissolve. Mix the solution by inverting the tube 5 times. Centrifuge to pool sample.|
|Storage||-20°C; Lyophilized from a 0.2 µm filtered solution of 20 mM PB and 150 mM NaCl, pH7.2.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Advanced glycosylation end product-specific receptor, also known as receptor for advanced glycosylation end products, AGER and RAGE, belongs to the immunoglobulin superfamily of cell surface molecules. It lies within the major histocompatibility complex (MHC) class III region on chromosome 6. Besides AGEs, AGER is also able to bind other ligands which is thought to result in pro-inflammatory gene activation. It is known that AGER serves as a mediator of both acute and chronic vascular inflammation in certain conditions such as atherosclerosis and in particular as a complication of diabetes. Furthermore, it plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.
Neeper M.,et al.J. Biol. Chem. 267:14998-15004(1992).
Sugaya K.,et al.Genomics 23:408-419(1994).
Abedin M.J.,et al.Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
Malherbe P.,et al.Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
Yonekura H.,et al.Biochem. J. 370:1097-1109(2003).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.